CustomerValidation
- •JClinInvest.2016Jan;126(1):112-22.
- •JPhysiol.2015Aug1;593(15):3333-50.
- •JPhysiol.2015Mar15;593(6):1459-77.
- •JPhysiol.2014Nov15;592(Pt22):4969-93.
- •CellSignal.2017May20;37:12-30.
- •CellCalcium.2016Jul;60(1):25-31.
- •AmJPhysiolHeartCircPhysiol.2016Dec1;311(6):H1352-H1359.
- •PflugersArch.2015Oct;467(10):2151-63.
- •BrainRes.2016Aug1;1644:249-57.
- •BiochemBiophysRep.2017Mar;9:245-256.
- •JACCBasicTranslSci.2016Jun;1(4):251-266.
Description | SEA0400isanovelandselectiveinhibitoroftheNa+-Ca2+exchanger(NCX),inhibitingNa+-dependentCa2+uptakeinculturedneurons,astrocytes,andmicrogliawithIC50soffrom5to33nM. |
---|---|
IC50&Target | IC50:5-33nM(NCX) |
InVitro | SEA0400inhibitsNa+-dependent45Ca2+uptakeinculturedneurons,astrocytes,andmicroglia.IC50valuesofSEA0400are33nM(neurons),5.0nM(astrocytes),and8.3nM(microglia)[1].SEA0400preventssodiumnitroprusside(SNP)toincreaseERKandp38MAPKphosphorylation,andproductionofreactiveoxygenspecies(ROS)inanextracellularCa2+-dependentmanner[2]. |
InVivo | SEA0400(3mg/kg+3mg/kg/hfor2h,i.v.)attenuatestheinfarctvolumeinthecerebralcortexandstriatum,doesnotaffectthemeantheregionalcorticalbloodflowinanesthetizedrats[1].SEA0400protectsagainstthedopaminergicneurotoxicity(determinedbydopaminelevelsinthemidbrainandstriatum,tyrosinehydroxylaseimmunoreactivityinthesubstantianigraandstriatum,striataldopaminerelease,andmotordeficits)inMPTP-treatedC57BL/6Jmice[3]. |
References |
|
PreparingStockSolutions |
Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent. | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
KinaseAssay [1] | Na+-Ca2+exchangeactivityisdeterminedbyassayingNa+-dependent45Ca2+uptakeasreportedpreviously.Briefly,thecellsarepreincubatedinHanks"balancedsalinesolution(HBSS)for20min,andthemediumisswitchedtoHBSScontaining45Ca2+ andincubatedfor5min.ToincreaseintracellularNa+ concentration,1mMouabainplus20μMmonensin(forastrocytesandmicroglia)and10μMmonensin(forneurons)areused.Monensinisaddedsimultaneouslywiththeisotope.Ouabainisadded5minbeforemonensininastrocytesandmicroglia.SEA0400andKB-R7943areadded5minbeforemonensinandpresentduring45Ca2+ uptakereaction.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||
CellAssay [1] | SEA0400isdissolvedinDMSO(finalconcentration0.1%). Cells,platedin96-wellplastictissuecultureplates,areincubatedat37°Cfor30mininnormalorCa2+-freeHBSScontaining10μMH2DCF-DAand0.25μg/mLCremophorEL,andthenrinsedtwicewithnormalHBSStoremoveexcessdye.ThecellsarereperfusedinnormalHBSSfor1h,andtheconversionofH2DCF-DAtoitsfluorescentproductdichlorofluoresceinbyROS,presumablyH2O2andhydroxylrADIcal,isdeterminedwithexcitationat485nmandemissionat535nmusingaWallacMultilabelcounter.ROSproductionisexpressedasapercentageofcontrolcells.ThelinearityandsensitivityofROSassayareconfirmedusingH2O2priortotheexperiment.SEA0400attheindicatedconcentrationsisadded10minbeforeCa2+ reperfusionandpresentuntilassay. MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||
AnimalAdmiNISTration [1] | SEA0400isadministratedasalipidemulsioncontaining20%soybeanoil. MaleSprague-Dawleyrats,weighing289to325g,areanesthetizedwith1to2%halothane.Acatheterisinsertedintothefemoralarteryandconnectedtoapressuretransducertorecordbloodpressure.RegionalcorticalbloodflowismeasuredbyalaserDopplerflowmeter,withprobeplacementat2mmposteriorand6mmlateraltothebregma.SEA0400oritsvehiclewithanequivalentvolumeisi.v.injectedat3mg/kgandtheninfusedat3mg/kg/hfor2hundernormalconditionswithoutMCAocclusion.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. | ||||||||||||||||
References |
|
MolecularWeight | 371.38 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formula | C₂₁H₁₉F₂NO₃ | ||||||||||||
CASNo. | 223104-29-8 | ||||||||||||
Storage |
| ||||||||||||
Shipping | RoomtemperatureincontinentalUS;mayvaryelsewhere | ||||||||||||
Solvent&Solubility | DMSO:≥32mg/mL *"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">1> Purity:99.89% 品牌介绍
托烷司琼临床评价药物相关作用适应症托烷司琼CAS号:89565-68-4英文名称:Tropisetron英文同义词:icf205-930;TROPICACID;TROPISETRON;SS-TROPISETRON;BETA-TROPISETRON;Tropisetron(ICS205930);TROPISHTRONHYDROCHLORIDE;Indole-3-carbonylchloride;3-Tropanylindole-3-carboxylate;lαH,5Αh-Tropan-3α-ylindole-3-carboxylate中文名称:托烷司琼中文同义词:托普西隆;托普西龙;曲匹西龙;托烷司琼;Β-托烷司琼;CS-348;Β-内托烷司琼;吲哚-3-甲酰氯;Β-托烷司琼(光学异构体);Β-托烷司琼,托烷司琼异构体CBNumber:CB3236404分子式:C17H20N2O2分子量:284.35MOLFile:89565-68-4.mol化学性质安全信息用途供应商112化学性质安全信息用途供应商112托烷司琼化学性质熔点:201-202°C沸点:448.5±35.0°C(Predicted)密度:1.26储存条件:2-8°C溶解度:H2O:soluble形态:solid酸度系数(pKa):15.38±0.30(Predicted)颜色:whiteCAS数据库:Chemicalbook89565-68-4(CASDataBaseReference)安全信息WGKGermany:3托烷司琼化学药品说明书托烷司琼|药物应用信息托烷司琼性质、用途与生产工艺临床评价Sorbe等报道本品对含顺铂(剂量50~89mg/m2)化疗方案引起的急性呕吐完全控制率为63%。58例恶性肿瘤化疗所致恶心、呕吐者,应用托烷司琼或昂丹司琼8mg分别在同一病人前后2个化疗周期的第1d给药前30min静脉注射,并用地塞米松10mg静脉滴注。结果两药控制急性及迟发性恶心、呕吐的疗效基本相似,均可达81%~100%。本品对强致吐化疗药物顺铂的止吐疗效突出。药物相关作用饮食可略为延长本品的吸收。本品与利福平、苯巴比妥等肝酶诱导药同时使用,可加快代谢,故快代谢型者需增加剂量,慢者则不必。西咪替丁等肝酶抑制药对本品血药浓度无明显影响。适应症托烷司琼临床用于预防和治疗癌症化疗引起的恶心和呕吐。化学性质结晶,熔点201-202℃(二氯甲烷-乙酸乙酯)。单盐酸托烷司琼(TropisetronMonohydroehloride):C17H20N2O2?HCI。[105826-92-4]。熔点283-285℃(分解)。用途有高效性和选择性的5-HT3受体拮抗剂。用于化疗所致的呕吐。用途为5-羟色胺拮抗药生产方法托品醇(I)和酰氯(Ⅱ)反应,可得托烷司琼。托烷司琼上下游产品信息上游原料托品醇下游产品
联络我们
|